Resistance to immunotherapies: Mechanisms to overcome acquired resistance

Webinar objectives

• Discuss new directions for selective pathogenic roles for IDO1 in metastatic vasculogenesis and retinopathy
• Identify novel tools for integrated screens with single-cell readouts
• Review predictive biomarkers for immunotherapy response and resistance
  
  

​Abcam is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.  Interested in receiving P.A.C.E credit for this educational session? Request credit here!
​

Speakers

• George Prendergast, The Lankenau Institute for Medical Research, USA
  • IDO/TDO targeting for cancer therapy: the path forward
  • Timestamp: 7:20 - 34:12
• Mari Mino-Kenudson, Massachusetts General Hospital, USA
  • Primary and acquired resistance to immunotherapies in lung cancer: Mechanisms and predictive biomarkers
  • Timestamp: 35:25 - 59:15
• Benjamin Izar, Columbia University, USA
  • Pooled screens with multi-modal single-cell profiling to define mechanisms of cancer immune evasion
  • Timestamp: 1:00:27 - 1:28:17
• Rüdiger Greinert, Elbekliniken Stade/Buxtehude, Germany
  • Use of a miRNA (FirePlex) assay for biomarker identification in clinical settings
  • ​Timestamp: 1:29:16 - 1:58:05